A Dark Vector Cognition product

Globe Life 10-Q 2026-09-30

GL · CIK 320335 · Form 10-Q · Period ended September 30, 2026 · Filed November 4, 2026

Revenue rose 5.5% to $1.60 billion. Net income was $361 million.

8 sections, 484K characters. Original on sec.gov · ·

Risk FactorsBusiness

Key numbers
MeasureQuarter ended Sep 30, 2026Quarter ended Sep 30, 2025Change
Revenue$1.60B$1.51B+5.5%
Net income$361M$388M-6.9%
Diluted EPS$4.62$4.73-2.3%

From the XBRL facts tagged to this filing; both columns are as reported in this filing.

The 128 tables in this filing as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Cover and table of contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark one)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2026

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 001-08052

GLOBE LIFE INC.

(Exact name of registrant as specified in its charter)

Delaware63-0780404
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)

7677 Henneman Way, McKinney, Texas 75070

(Address of principal executive offices) (Zip Code)

(972) 569-4000

(Registrant’s telephone number, including area code)

NONE

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $1.00 par value per shareGLNew York Stock Exchange
Common Stock, $1.00 par value per shareGLNYSE Texas, Inc.
4.250% Junior Subordinated DebenturesGL PRDNew York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

ClassOutstanding at October 30, 2026
Common Stock, $1.00 Par Value75,439,736

GL Q3 2026 FORM 10-Q

Globe Life Inc.

Table of Contents

Page
PART I****. FINANCIAL INFORMATION
Item 1.Condensed Consolidated Financial Statements
Condensed Consolidated Balance Sheets1
Condensed Consolidated Statements of Operations2
Condensed Consolidated Statements of Comprehensive Income (Loss)3
Condensed Consolidated Statements of Shareholders' Equity4
Condensed Consolidated Statements of Cash Flows6
Notes to Condensed Consolidated Financial Statements7
Note 1—Significant Accounting Policies7
Note 2—New Accounting Standards8
Note 3—Supplemental Information about Changes to Accumulated Other Comprehensive Income (Loss)9
Note 4—Investments11
Note 5—Commitments and Contingencies23
Note 6—Policy Liabilities25
Note 7—Deferred Acquisition Costs44
Note 8—Liability for Unpaid Claims47
Note 9—Postretirement Benefits48
Note 10—Earnings Per Share50
Note 11—Debt51
Note 12—Business Segments53
Note 13—Subsequent Events60
Cautionary Statements61
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations62
Item 3.Quantitative and Qualitative Disclosures About Market Risk92
Item 4.Controls and Procedures92
PART II**. OTHER INFORMATION**
Item 1.Legal Proceedings93
Item 1A.Risk Factors93
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds93
Item 5.Other Information93
Item 6.Exhibits94
Signatures95

As used in this Form 10-Q, “Globe Life,” the “Company,” “we,” “our” and “us” refer to Globe Life Inc., a Delaware corporation incorporated in 1979, its subsidiaries and affiliates.

GL Q3 2026 FORM 10-Q

PART I—FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements

Globe Life Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(Dollar amounts in thousands, except share and per share data)

September 30, 2026December 31, 2025
Assets:
Investments:
Fixed maturities—available for sale, at fair value (amortized cost: 2026—$19,564,388; 2025—$18,820,464, allowance for credit losses: 2026— $3,297; 2025— $3,297)$16,873,879$17,589,342
Mortgage loans459,302428,517
Policy loans771,652741,375
Other long-term investments (includes: 2026—$1,060,664; 2025—$1,109,719 under the fair value option)1,433,3011,396,064
Short-term investments95,244314,711
Total investments19,633,37820,470,009
Cash257,921144,704
Accrued investment income296,746272,818
Other receivables792,062768,592
Deferred acquisition costs7,350,4916,999,136
Goodwill490,446490,446
Other assets1,749,3731,667,987
Total assets$30,570,417$30,813,692
Liabilities:
Future policy benefits at current discount rates: (at original discount rates: 2026—$18,497,791; 2025—$18,129,506)$17,622,629$19,169,687
Unearned and advance premium275,478270,663
Policy claims and other benefits payable562,059540,832
Other policyholders' funds555,598532,047
Total policy liabilities19,015,76420,513,229
Current and deferred income taxes995,223859,628
Short-term debt317,618304,656
Long-term debt (estimated fair value: 2026—$2,429,900; 2025—$2,225,320)2,667,7692,320,793
Other liabilities955,559840,807
Total liabilities23,951,93324,839,113
Commitments and Contingencies (Note 5)
Shareholders' equity:
Preferred stock, par value $1 per share—5,000,000 shares authorized; outstanding: 0 in 2026 and 2025——
Common stock, par value $1 per share—320,000,000 shares authorized; outstanding: (2026—92,218,183 issued; 2025—92,218,183 issued)92,21892,218
Additional paid-in-capital550,542536,363
Accumulated other comprehensive income (loss)(1,416,943)(1,771,444)
Retained earnings9,370,6458,546,807
Treasury stock, at cost: (2026—16,155,340 shares; 2025—13,125,082 shares)(1,977,978)(1,429,365)
Total shareholders' equity6,618,4845,974,579
Total liabilities and shareholders' equity$30,570,417$30,813,692

See accompanying Notes to Condensed Consolidated Financial Statements.

GL Q3 2026 FORM 10-Q

Globe Life Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

(Dollar amounts in thousands, except share and per share data)

Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Revenue:
Life premium$864,552$844,483$2,578,524$2,513,890
Health premium446,857386,5241,300,6201,134,414
Total premium1,311,4091,231,0073,879,1443,648,304
Net investment income295,895286,013879,539848,796
Realized gains (losses)(12,612)(4,987)(6,952)(23,476)
Other income1,2459553,5551,073
Total revenue1,595,9371,512,9884,755,2864,474,697
Benefits and expenses:
Life policyholder benefits(1)414,701381,5111,447,5101,410,622
Health policyholder benefits(2)272,129227,940812,875691,793
Other policyholder benefits7,2687,17121,54820,970
Total policyholder benefits694,098616,6222,281,9332,123,385
Amortization of deferred acquisition costs124,654114,074363,473330,990
Commissions, premium taxes, and non-deferred acquisition costs174,863157,494518,503479,228
Other operating expense123,274111,562353,260328,601
Interest expense37,81436,134107,864106,011
Total benefits and expenses1,154,7031,035,8863,625,0333,368,215
Income before income taxes441,234477,1021,130,2531,106,482
Income tax benefit (expense)(80,127)(89,259)(210,873)(211,327)
Net income$361,107$387,843$919,380$895,155
Basic net income per common share$4.71

Showing the first 8K of 334K characters. Open the full section

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with Globe Life's Condensed Consolidated Financial Statements and Notes thereto appearing elsewhere in this report. The following management discussion will only include comparison to prior year.

"Globe Life" and the "Company" refer to Globe Life Inc. and its subsidiaries and affiliates.

Results of Operations

How Globe Life Views Its Operations. Globe Life Inc. is the holding company for a group of insurance companies that market through exclusive, direct-to-consumer and independent distribution channels primarily individual life and supplemental health insurance to lower middle to middle-income households throughout the United States. We view our operations by segments, which are the insurance product lines of life and supplemental health, and the investment segment that supports the product lines.
Insurance Product Line Segments. The insurance product line segments involve the marketing, underwriting, and administration of policies. Each product line is further subdivided by the various distribution channels that market the insurance policies. Each distribution channel operates in a niche market offering insurance products designed for that particular market. Whether analyzing profitability of a segment as a whole, or the individual distribution channels within the segment, the measure of profitability used by management is the underwriting margin, as seen below:
Premium revenue (Policy obligations) (Policy acquisition costs and commissions) Underwriting margin
Investment Segment. The investment segment involves the management of our capital resources, including investments and the management of liquidity. Our measure of profitability for the investment segment is excess investment income, as seen below:
Net investment income (Required interest on policy liabilities) Excess investment income

GL Q3 2026 FORM 10-Q

GLOBE LIFE INC.

Management's Discussion & Analysis

Globe Life serves the lower-middle to middle-income market. We believe this market is underserved, has significant growth potential, and provides us with a distinct competitive advantage. This advantage is protected due not only to our ability to efficiently reach this market through both exclusive and direct to consumer distribution channels, but also due to the amount of data and experience we possess, as we have been in this same market for over 60 years with essentially the same products. The basic protection life and health insurance products we offer are specifically designed to help provide financial security to consumers in this market.

Current Highlights.

  • On a diluted basis, net income per common share increased 8% from $10.77 to $11.64 and net operating income per common share increased from $11.13 to $11.86, a 7% increase over the prior year period.

  • Net income as a return on equity (ROE) for the nine months ended September 30, 2026 was 19.7% and net operating income as an ROE, excluding accumulated other comprehensive income(1), was 15.9%.

  • Total premium increased 6% over the same period in the prior year. Life premium increased 3% for the period from $2.5 billion in 2025 to $2.6 billion in 2026. Health premium increased 15% to $1.3 billion from $1.1 billion over the prior-year period.

  • Total net sales increased 10% over the same period in the prior year from $661 million in 2025 to $727 million in 2026. Average producing agent count increased by 9% at Liberty National Division and 6% at Family Heritage Division.

  • Book value per share increased 23% over the same period in the prior year from $69.52 to $85.35. Book value per share, excluding accumulated other comprehensive income**(1)**, increased 11% over the prior year from $93.63 in 2025 to $103.62 in 2026.

  • For the nine months ended September 30, 2026, the Company repurchased 3.6 million shares of Globe Life Inc. common stock at a total cost of $564 million for an average share price of $155.30.

The following graphs represent net income and net operating income(1) for the nine month periods ended September 30, 2026 and 2025.

1618 1620

(1)As shown in the charts above, net operating income is primarily comprised of insurance underwriting margin plus excess investment income and annuity and other income, offset by operating expenses after tax and, as such, is considered a non-GAAP measure. It has been used consistently by Globe Life's management for many years to evaluate the operating performance of the Company. Net operating income differs from net income primarily because it excludes certain non-operating items such as realized gains and losses and certain significant and unusual items included in net income. Net income is the most directly comparable GAAP measure.

Net operating income as an ROE, excluding AOCI, is considered a non-GAAP measure. Management utilizes this measure to view the business without the effect of changes in AOCI, which are primarily attributable to fluctuation in interest rates. The impact of the adjustment to exclude AOCI is $(1.4) billion and $(2.0) billion for the nine months ended September 30, 2026 and 2025, respectively.

Book value per share, excluding AOCI, is also considered a non-GAAP measure. Management utilizes this measure to view the book value of the business without the effect of changes in AOCI, which are primarily attributable to fluctuation in interest rates. The impact of the adjustment to exclude AOCI is $(18.27) and $(24.11) per share for the nine months ended September 30, 2026 and 2025, respectively.

Refer to Analysis of Profitability by Segment for non-GAAP reconciliation to GAAP.

GL Q3 2026 FORM 10-Q

GLOBE LIFE INC.

Management's Discussion & Analysis

Summary of Operations.

  • Net income totaled $919 million during the nine months ended September 30, 2026, compared with $895 million, in the same period in 2025, an increase of 3%.

  • On a diluted basis, net income per common share for the nine months ended September 30, 2026 increased 8% from $10.77 to $11.64.

  • Net operating income was $937 million for the nine months ended September 30, 2026, compared with $925 million for the same period in 2025, an increase of 1%.

  • On a diluted basis, net operating income per common share for the nine months ended September 30, 2026 increased from $11.13 to $11.86, a 7% increase.

Net operating income is primarily comprised of insurance underwriting margin plus excess investment income and annuity and other income, offset by operating expenses, after tax and, as such, is considered a non-GAAP measure. Net income is the most directly comparable GAAP measure. We do not consider realized gains and losses to be a component of our core insurance operations or operating segments. Additionally, net income is affected by certain non-operating items. We do not view these items as components of core operating results because they are not indicative of past performance or future prospects of the insurance operations. We remove items such as these which relate to prior periods or are non-operating items when evaluating the results of current operations, and therefore exclude such items from our segment analysis for current periods.

During the third quarter of 2026, the Company performed its annual assumptions review and updated both its life and health assumptions of lapses, mortality, and morbidity resulting in a $120.5 million net remeasurement gain as compared to a $134.3 million net remea

Showing the first 8K of 131K characters. Open the full section

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no quantitative or qualitative changes with respect to market risk exposure during the nine months ended September 30, 2026.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures: Globe Life Inc., under the direction of the Co-Chairmen and Chief Executive Officers and the Executive Vice President and Chief Financial Officer, has established disclosure controls and procedures that are designed to ensure that information required to be disclosed by Globe Life in the reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. The disclosure controls and procedures are also intended to ensure that such information is accumulated and communicated to Globe Life's management, including the Co-Chairmen and Chief Executive Officers and the Executive Vice President and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.

As of the end of the fiscal period completed September 30, 2026, an evaluation was performed under the supervision and with the participation of Globe Life management, including the Co-Chairmen and Chief Executive Officers and the Executive Vice President and Chief Financial Officer, of the disclosure controls and procedures (as those terms are defined in Rule 13a-15(e) under the Securities Exchange Act of 1934). Based upon their evaluation, the Co-Chairmen and Chief Executive Officers and the Executive Vice President and Chief Financial Officer have concluded that disclosure controls and procedures are effective as of the date of this Form 10-Q. In compliance with Section 302 of the Sarbanes Oxley Act of 2002 (18 U.S.C. § 1350), each of these officers executed a Certification included as an exhibit to this Form 10-Q.

Changes in Internal Control over Financial Reporting: During the period ended September 30, 2026, there were no changes to Globe Life Inc.'s internal control over financial reporting or in other factors that could significantly affect the internal control over financial reporting subsequent to the date of their evaluation which have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

GL Q3 2026 FORM 10-Q

Part II—Other Information

Item 1. Legal Proceedings

Discussion regarding litigation is provided in Note 5—Commitments and Contingencies.

Item 1A. Risk Factors

The Company had no material changes to its risk factors.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Purchases of Certain Equity Securities by the Issuer and Others for the Third Quarter of 2026

Period(a) Total Number of Shares Purchased(b) Average Price Paid Per Share(c) Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(d) Maximum Number of Shares (or Approximate Dollar Amount) that May Yet Be Purchased Under the Plans or Programs
July 1-31, 2026353,745$178.79353,745—
August 1-31, 2026568,400177.37568,400—
September 1-30, 2026306,149170.56306,149—

Item 5. Other Information

(c) Trading arrangements

During the nine months ended September 30, 2026, none of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a Non-Rule 10b5-1 trading arrangement, as each term is defined under Item 408(a) of Regulation S-K.

GL Q3 2026 FORM 10-Q

Item 6. Exhibits

Exhibit No.Description
10.1Form of Seven Year Stock Option under Globe Life Inc. 2026 Incentive Plan
10.2Form of Seven Year Stock Option under Globe Life Inc. 2026 Incentive Plan with Non-Compete, Non-Solicit and Confidentiality Provisions
10.3Form of Restricted Stock Unit Award Agreement under Globe Life Inc. 2026 Incentive Plan
10.4Form of Restricted Stock Unit Award Agreement under Globe Life Inc. 2026 Incentive Plan with Non-Compete, Non-Solicit and Confidentiality Provisions
10.5Form of Performance Share Award Certificate under Globe Life Inc. 2026 Incentive Plan
31.1Rule 13a-14(a)/15d-14(a) Certification by J. Matthew Darden
31.2Rule 13a-14(a)/15d-14(a) Certification by Frank M. Svoboda
31.3Rule 13a-14(a)/15d-14(a) Certification by Thomas P. Kalmbach
32.1Section 1350 Certification by J. Matthew Darden, Frank M. Svoboda, and Thomas P. Kalmbach
101.INSXBRL Instance Document- the instance document does not appear in the Interactive Data file because the XBRL tags are embedded within the Inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document.
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.
101.LABInline XBRL Taxonomy Extension Label Linkbase Document.
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.
104Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101).

GL Q3 2026 FORM 10-Q

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

GLOBE LIFE INC.
Date: November 4, 2026/s/ J. Matthew Darden
J. Matthew Darden
Co-Chairman and Chief Executive Officer
Date: November 4, 2026/s/ Frank M. Svoboda
Frank M. Svoboda
Co-Chairman and Chief Executive Officer
Date: November 4, 2026/s/ Thomas P. Kalmbach
Thomas P. Kalmbach
Executive Vice President and Chief Financial Officer

GL Q3 2026 FORM 10-Q